Lidokain Aguettant

Lidocaine Hydrochloride, the active ingredient in Lidokain Aguettant, is a local anesthetic presented as a sterile solution for infiltration, intradermal and subcutaneous use. It provides rapid, reversible loss of sensation in targeted tissues for minor procedures.

GNH USA supplies Lidokain Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine Hydrochloride is used to provide local anesthesia in various procedural settings.

- Minor surgical procedures: rapid onset anesthesia to facilitate incision and excision. - Dental procedures: numbs oral tissues for extractions, restorations and periodontal work. - Dermatologic procedures: anesthetizes skin for biopsies, excisions, laser treatments and cosmetic interventions.

Lidocaine Hydrochloride may cause adverse reactions at the injection site or systemically.

Common Side Effects: - Burning or stinging sensation at the injection site. - Mild redness or swelling of the treated area. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction (severe allergy). - Cardiac arrhythmias, including ventricular tachycardia. - Central nervous system toxicity such as seizures or loss of consciousness.

When using Lidokain Aguettant, consider the following precautions: - Allergy assessment: verify no known hypersensitivity to lidocaine or amide‑type anesthetics. - Dose limitation: employ the lowest effective amount to stay within recommended maximum dose. - Cardiac monitoring: observe patients with pre‑existing heart disease for arrhythmias. - Aspiration before injection: avoid inadvertent intravascular administration. - Pregnancy and lactation: use only if the clinical benefit outweighs potential risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lidokain Aguettant can interact with other medications; awareness of the interaction level is essential.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): increase systemic toxicity. - Beta‑blockers (e.g., propranolol): may potentiate cardiac depressant effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Concurrent use of other local anesthetics: cumulative toxicity risk. - Diuretics (e.g., furosemide): may reduce plasma protein binding, enhancing free drug levels. - General anesthetics (e.g., propofol): additive central nervous system depression.